FI964332A0 - Användning av vissa metanbisfofonsyraderivat för att hindra förslappning och vandring av protes - Google Patents

Användning av vissa metanbisfofonsyraderivat för att hindra förslappning och vandring av protes

Info

Publication number
FI964332A0
FI964332A0 FI964332A FI964332A FI964332A0 FI 964332 A0 FI964332 A0 FI 964332A0 FI 964332 A FI964332 A FI 964332A FI 964332 A FI964332 A FI 964332A FI 964332 A0 FI964332 A0 FI 964332A0
Authority
FI
Finland
Prior art keywords
prosthesis
migration
acid derivatives
pct
relaxation
Prior art date
Application number
FI964332A
Other languages
English (en)
Finnish (fi)
Other versions
FI118590B (sv
FI964332A (sv
Inventor
Allen E Goodship
John Kenwright
Jonathan Green
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of FI964332A0 publication Critical patent/FI964332A0/sv
Publication of FI964332A publication Critical patent/FI964332A/sv
Application granted granted Critical
Publication of FI118590B publication Critical patent/FI118590B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Chemical Treatment Of Metals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Dental Preparations (AREA)
FI964332A 1994-05-04 1996-10-28 Användning av 1-hydroksi -2- (imidazol -1-yl) etan -1,1 -difosfonsyra för att hindra glapp och migration av en protes FI118590B (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9408775A GB9408775D0 (en) 1994-05-04 1994-05-04 Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration
GB9408775 1994-05-04
IB9500288 1995-04-24
PCT/IB1995/000288 WO1995030421A1 (en) 1994-05-04 1995-04-24 Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration

Publications (3)

Publication Number Publication Date
FI964332A0 true FI964332A0 (sv) 1996-10-28
FI964332A FI964332A (sv) 1996-10-28
FI118590B FI118590B (sv) 2008-01-15

Family

ID=10754497

Family Applications (1)

Application Number Title Priority Date Filing Date
FI964332A FI118590B (sv) 1994-05-04 1996-10-28 Användning av 1-hydroksi -2- (imidazol -1-yl) etan -1,1 -difosfonsyra för att hindra glapp och migration av en protes

Country Status (18)

Country Link
US (1) US5965547A (sv)
EP (1) EP0758241B1 (sv)
JP (1) JPH09512816A (sv)
AT (1) ATE218350T1 (sv)
AU (1) AU693541B2 (sv)
DE (1) DE69526937T2 (sv)
DK (1) DK0758241T3 (sv)
ES (1) ES2177642T3 (sv)
FI (1) FI118590B (sv)
GB (1) GB9408775D0 (sv)
HU (1) HUT74984A (sv)
IL (1) IL113566A (sv)
NO (1) NO310057B1 (sv)
NZ (1) NZ283430A (sv)
PT (1) PT758241E (sv)
TW (1) TW458779B (sv)
WO (1) WO1995030421A1 (sv)
ZA (1) ZA953537B (sv)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
US6117856A (en) * 1996-02-14 2000-09-12 Binderman; Itzhak Topical bisphosphonates for prevention of bone resorption
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
US5994329A (en) * 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
GB2336311A (en) * 1998-04-15 1999-10-20 Merck & Co Inc Bisphosphonate Dosing Regimen
US6137012A (en) 1998-10-13 2000-10-24 E. I. Du Pont De Nemours And Company Phosphole and diphosphole ligands for catalysis
BR9915927A (pt) 1998-12-04 2001-08-21 Roche Diagnostics Gmbh Uso de ácido ibandrÈnico ou seus sais ou ésteres fisiologicamente compatìveis
CA2360319A1 (en) * 1999-02-09 2000-08-17 Memorial Sloan-Kettering Cancer Center Anti-resorptive bone cements and allogeneic, autografic, and xenografic bone grafts
EP1118328A1 (en) * 1999-08-02 2001-07-25 Toray Industries, Inc. Insertion stabilizers for implants
AUPQ232599A0 (en) * 1999-08-19 1999-09-09 Royal Alexandra Hospital For Children, The Drug for treating fractures
SI1591122T1 (sl) 2000-06-20 2013-02-28 Novartis Ag Postopek za aplikacijo bisfosfonatov
NZ523086A (en) * 2000-06-20 2007-07-27 Novartis Ag Method of administering bisphosphonates
AU2001287260A1 (en) * 2000-07-12 2002-01-21 Ecole Polytechnique Federale De Lausanne (Epfl) Active biocoating for bone implant
GB0029111D0 (en) * 2000-11-29 2001-01-10 Novartis Ag Organic compounds
CA2347330C (en) * 2001-05-10 2002-03-12 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
JP2005522526A (ja) * 2002-05-10 2005-07-28 エフ．ホフマン−ラ　ロシュ　アーゲー 骨粗鬆症の治療および予防用のビスホスホン酸
ES2376425T3 (es) * 2002-09-16 2012-03-13 Novartis Ag �?cido zoledrónico para prevenir o reducir fracturas secundarias tras fractura de cadera.
US20040138180A1 (en) * 2002-10-03 2004-07-15 Barr Laboratories, Inc. Bisphosphonate composition and process for the preparation thereof
US8071574B2 (en) * 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
CA2669488A1 (en) * 2006-11-17 2008-05-22 Besins Healthcare Pharmaceutical compositions comprising a bisphosphonate compound
EP1958649A1 (en) * 2007-02-14 2008-08-20 Graftys Injectable calcium-phosphate cement releasing a bone resorption inhibitor
EP2136814A4 (en) * 2007-03-21 2012-05-30 Univ Duke MEDICAL KITS AND FORMULATIONS FOR PREVENTING, TREATING OR REDUCING SECONDARY FRACTURES FROM A PREVIOUS FRACTURE
WO2008152518A2 (en) * 2007-05-16 2008-12-18 Actavis Group Ptc Ehf Process for the preparation of risedronic acid or risedronate sodium
US9867838B2 (en) 2009-09-01 2018-01-16 Duke University Methods for treating heart failure using bisphosphonate compositions
US8882740B2 (en) * 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone
CN104010647A (zh) 2011-11-16 2014-08-27 杜克大学 用于治疗和/或减轻心功能障碍的双膦酸盐组合物及方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2405254C2 (de) * 1974-02-04 1982-05-27 Henkel KGaA, 4000 Düsseldorf Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsäure oder ihrer wasserlöslichen Salze bei der Beeinflußung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper
US4639338A (en) * 1984-08-06 1987-01-27 Ciba-Geigy Corporation Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
ES2038692T4 (es) * 1986-11-21 2012-02-10 Novartis Ag Procedimiento para la obtencion de acidos alcanodifosfonicos substituidos.
JPH05163150A (ja) * 1991-05-13 1993-06-29 E R Squibb & Sons Inc アテローム性動脈硬化症の抑制・治療剤
US5403829A (en) * 1993-03-24 1995-04-04 Leiras Oy Use of bisphosphonates in endo-osteal bone surgery
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices

Also Published As

Publication number Publication date
HUT74984A (en) 1997-03-28
EP0758241B1 (en) 2002-06-05
ZA953537B (en) 1995-11-06
DE69526937T2 (de) 2003-01-02
NO964486L (no) 1996-10-22
US5965547A (en) 1999-10-12
TW458779B (en) 2001-10-11
NO310057B1 (no) 2001-05-14
NO964486D0 (no) 1996-10-22
FI118590B (sv) 2008-01-15
IL113566A0 (en) 1995-08-31
ATE218350T1 (de) 2002-06-15
DK0758241T3 (da) 2002-09-23
AU693541B2 (en) 1998-07-02
GB9408775D0 (en) 1994-06-22
HU9603042D0 (en) 1997-01-28
FI964332A (sv) 1996-10-28
NZ283430A (en) 2000-06-23
JPH09512816A (ja) 1997-12-22
WO1995030421A1 (en) 1995-11-16
AU2146695A (en) 1995-11-29
EP0758241A1 (en) 1997-02-19
PT758241E (pt) 2002-10-31
DE69526937D1 (de) 2002-07-11
IL113566A (en) 2002-05-23
ES2177642T3 (es) 2002-12-16

Similar Documents

Publication Publication Date Title
FI964332A0 (sv) Användning av vissa metanbisfofonsyraderivat för att hindra förslappning och vandring av protes
DE69326776D1 (de) Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress
NO952229L (no) Anvendelse av karbamazepin og okskarbazepin ved behandling av neurologiske lesjoner relatert til traumatiske skader
DE69507029D1 (de) Pharmazeutische zusammensetzungen enthaltend einen opiat antagonist und calcium salze, ihre verwendung zur behandlung von endorphin-vermittelten krankheiten
DE69400435D1 (de) Verwendung von carbamazepine und oxcarbazepine zur behandlung von parkinson und den parkinson-syndromen
ATE216877T1 (de) Verwendung von nsaids zur behandlung von plattenepithelkarzinom der mundhöhle und kehlkopf
DE69518767D1 (de) Ondasetronhaltige oral anzuwendende arzneimittel
FI964789A0 (sv) Pefluoralkylketoninhibitorer av elastas och förfaranden för framställning av dem
DE59401401D1 (de) Pharmazeutische formulierung zur behandlung der nicotinabhängigkeit
FI972308A (sv) 2-substituerade 1,2,5-tiadiazolidin-3-oni-1,1-dioxider och dessa innehållande kompositioner och förfarande för deras användning
DE69431601D1 (de) Neue verwendung von dexmedetomidin
IT1282736B1 (it) Uso di derivati del p-amminofenolo per preparare composizioni farmaceutiche utili nel trattamento di malattie neurodegenerative
IL115589A0 (en) Use of cck-b antagonists in pharmaceutical compositions
BG105275A (en) Tan-1057 derivatives
AU3862997A (en) Stable derivatives of ubiquinole, processes for their production and pharmaceutical use thereof
EE9700366A (et) Angiotensiini II tüüp 1 retseptori antagonistide kasutamine düspeptiliste sümptomite profülaktikas ja/või ravis kasutatava ravimi valmistamiseks ja angiotensiini II tüüp 1 retseptori antagoniste sisaldavad ravimpreparaadid
MX9605327A (es) Uso de ciertos derivados de acido metanbisfosfonico para prevenir el aflojamiento de las protesis y la emigracion de las protesis.
ATE312611T1 (de) Verwendung von mizolastine zur herstellung eines arzneimittels zur behandlung von entzündungen
ATA57894A (de) Mittel zur behandlung von osteoporose
IL108283A0 (en) Use of riluzole for promoting restoration following radiation
NZ304823A (en) Beta carboline derivatives and medicaments

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: NOVARTIS AG

FG Patent granted

Ref document number: 118590

Country of ref document: FI